Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 168-174 , May 2011

Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy

  • Hala O. Al-Mesallamy

      Affiliations

    • Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt
    • ,
  • Lamiaa N. Hammad

      Affiliations

    • Biochemistry Department, Faculty of Pharmacy, Misr International University, Cairo, Egypt
    • ,
  • Tarek A. El-Mamoun

      Affiliations

    • Opthalmology Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt
    • ,
  • Basma M. Khalil

      Affiliations

    • Biochemistry Department, Faculty of Pharmacy, Misr International University, Cairo, Egypt
    • Corresponding Author InformationCorresponding author. Biochemistry Department, Faculty of Pharmacy, Misr International University, Km 28 Cairo-Ismailia Road, Orabi District, P.O. Box 1, Heliopolis, Cairo, Egypt. Tel.: +20 2 0101510719; fax: +20 2 44771566.

Received 17 January 2010 ,Revised 1 June 2010 ,Accepted 23 June 2010.

References 

  1. Aiello LM. Perspectives on diabetic retinopathy. American Journal of Ophthalmology. 2003;136(1):122–135
  2. Anitha B, Sampathkumar R, Balasubramanyam M, Rema M. Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. Journal of Diabetes and Its Complication. 2008;22:261–266
  3. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9–21
  4. Caldwell RB, Zhang W, Romero MJ, Caldwell RW. Vascular dysfunction in retinopathy: an emerging role for arginase. Brain Research Bulletin. 2010;81:303–309
  5. Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. Progress in Retinal and Eye Research. 2008;27:161–176
  6. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema pathophysiology, screening, and novel therapies. Diabetes Care. 2003;29:2653–2663
  7. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, et al. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. Journal of Clinical Investigation. 2003;112:1049–1057
  8. Fong DS, Aiello L, Gardner TW. American Diabetes Association. Diabetic retinopathy. Diabetes Care. 2003;26:226–229
  9. Gohda T, Tanimoto M, Moon J-Y, Gotoh H, Aoki T, Matsumoto M, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Research and Clinical Practice. 2008;81:196–201
  10. Grossin N, Wautier M-P, Measb T, Guillausseau P-J, Massin P, Wautier J-L. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes & Metabolism. 2008;34:392–395
  11. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. International Journal of Biochemistry and Cell Biology. 2004;36:1206–1237
  12. Katakami N, Matsuhisa M, Kaneto H, Matsuoka T, Sakamoto K, Yasuda T, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis. 2009;204:288–292
  13. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Experimental Diabetes Research. 2007;2007:1–14
  14. Lapolla A, Traldi P, Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clinical Biochemistry. 2005;38:103–115
  15. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes and Vascular Disease Research. 2009;6:7–14
  16. Miura J, Uchigata Y, Yamamoto Y, Takeuchi M, Sakurai S, Watanabe T, et al. AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes. Journal of Diabetes and Its Complications. 2004;18:53–59
  17. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902–916
  18. Motiejunaite R, Kazlauskas A. Pericytes and ocular diseases. Experimental Eye Research. 2008;86:171–177
  19. Nakamura K, Yamagishi S, Adachi H, Matsui T, Nakamura YK, Takeuchi M, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvascular Research. 2008;76:52–56
  20. Nessar A. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Research and Clinical Practice. 2005;67:3–21
  21. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. Journal of the American College of Cardiology. 2009;53:S35–S42
  22. Park KS, Kim SS, Kim JC, Kim HC, Im YS, Ahn CW, et al. Serum and tear levels of nerve growth factor in diabetic retinopathy patients. American Journal of Opthalmology, 145, 432-. 2008;437
  23. Pereira EC, Ferderbar S, Bertolami MC, Faludi AA, Monte O, Xavier HT, et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clinical Biochemistry. 2008;41:1454–1460
  24. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Research and Clinical Practice. 2006;73:158–165
  25. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clinical Science. 2005;109:143–159
  26. Siemianowicz K, Francuz T, Gminski J, Telega A, Syzd M. Endothelium dysfunction markers in patients with diabetic retinopathy. International Journal of Molecular Medicine. 2005;15:459–462
  27. Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Annals of International Medicine. 2003;138:587–592
  28. Sulochana KN, Ramakrishnan S, Rajesh M, Coral K, Badrinath SS. Diabetic retinopathy: molecular mechanisms, present regime of treatment and future perspectives. Current Science. 2001;80(2):1–25
  29. Trinder P. Determination of blood glucose using 4-aminophenazone as oxygen acceptor. Journal of Clinical Pathology. 1969;22:246
  30. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvascular Research. 2008;75:130–134
  31. Yokoi M, Yamagishi S, Takeuchi M, Matsui T, Yoshida Y, Ohgami K, et al. Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. British Journal of Ophthalmology. 2007;91:397–405
  32. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin J, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes induced vascular injury. Biochemical Journal. 2003;370:1097–1109
  33. Yonem A, Duran C, Unal M, Ipcioglu OM, Ozcan O. Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy. Diabetes Research and Clinical Practice. 2009;84:219–223

PII: S1056-8727(10)00070-X

doi: 10.1016/j.jdiacomp.2010.06.005

Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 168-174 , May 2011

Article Tools

* Image Usage & Resolution